Abstract
The incidence of adenocarcinoma of the exocrine pancreas is steadily increasing. Approximately 25000 new cases of pancreatic cancer are diagnosed yearly in the United States where this tumor now ranks as the fourth leading cause of death from malignancies (Connolly et al. 1987; Greenberger et al. 1987). The vast majority of pancreatic cancers are ductal adenocarcinomas, but other pancreatic carcinomas also occur. Histogenetically, more than 90% of these tumors are derived from the pancreatic ducts and thus about 60% are located in the head of the gland (Moossa et al. 1986). Ductal adenocarcinoma has a very poor prognosis, in part because most patients have advanced disease by the time of diagnosis. Early diagnosis and screening for nonendocrine pancreatic cancer is difficult, although the technology for detecting these small tumors is available (Blind and Dahlgren 1987; Douglass 1987; Anonymous 1986; Malt 1983).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anonymous (1986) Early diagnosis and screening for pancreatic cancer (editorial). Lancet ii:785–786
Bauer W, Briner W, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS-201-995: a very potent and selective octapeptide analogue of somatostatin with prolongued action. Life Sci 31:1133–1140
Benz C, Hollander C, Miller B (1986) Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 46:2276
Blind PJ, Dahlgren ST (1987) Serum levels of the carbohydrate antigen CA-50 in pancreatic disease. Acta Chir Scand 153:45–49
Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV (1986) Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci USA 83:1896–1900
Cai RZ, Karashima T, Guoth J, Szoke B, Olsen D, Schally AV (1987) Superactive octapeptide somatostatin analogs containing tryptophan residue in position 1. Proc Natl Acad Sci USA 84:2502–2506
Chester JF, Gaissert HA, Ross JS, Malt RA (1986) Pancreatic cancer in the Syrian hamster induced by N-Nitrobis(2-oxopropyl)amine: cocarcinogenic effect of epidermal growth factor. Cancer Res 46:2954–2957
Comaru-Schally AM, Schally AV (1988) LH-RH agonists as adjuncts to somatostatin analogs in the treatment of pancreatic cancer. In: Lunenfeld B, Vickery B (eds) International symposium on Gn-RH analogues in cancer and human reproduction. MTP Press, Geneva
Connolly MM, Dawson PJ, Michelassi F, Moossa AR, Lowenstein F (1987) Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 206:386
Corbishley TP, Iqbal MJ, Wilkinson ML, Williams R (1986) Androgen receptor in human normal and malignant pancreatic tissue and cell lines. Cancer 57:1992
Dembinski AB, Johnson LR (1980) Stimulation of pancreatic growth by secretin cerulein and pentagastrin. Endocrinology 106:323–328
Douglass HO Jr (1987) Pancreatic cancer: nihilism is obsolete Pancreas 2:230–232
Fekete M, Zalatnai A, Comaru-Schally AM (1989) Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4:521–528
Gonzalez-Barcena D, Rangel-Garcia NE, Perez-Sanchez PL, Gutierrez-Samperio C, Garcia-Carrasco F, Comaru-Schally AM, Schally AV (1986) Response to D-Trp6-LH-RH in advanced adenocarcinoma of pancreas. Lancet ii: 154
Gonzalez-Barcena D, Ibarra-Olmos MA, Garcia-Carrasco F, Gutierrez-Samperio C, Comaru-Schally AM, Schally AV (1989) Influence of D-Trp6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother 43:1–5
Goustin AS, Leof EB, SMpley GD, Moses HL (1986) Growth factors and cancer. Cancer Res 46:1015–1029
Greenberger JJ, Toskes PP, Isselbacher KJ (1987) Diseases of the pancreas. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS (eds) Harrison’s principles of internal medicine, 11th edn. MacGraw-Hill, New York, pp 1372–1383
Greenway B, Duke D, Pym B, Iqbal MJ, Johnson PJ, Williams R (1982) The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br J Surg 69:595
Hierowski MT, Liebow C, Du Spain K, Schally AV (1985) Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett 179:252–256
Johnson LR (1981) Effects of gastrointestinal hormones on pancreatic growth. Cancer 47:1640–1645
Kaiser MH, Ellenberg SS (Gastrointestinal Tumor Study Group) (1985) Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899
Konturek SJ, Tasler J, Obtulowicz W, Coy DH, Schally AV (1976) Effect of growth hormone releasing inhibiting hormone on hormones stimulating exocrine pancreatic secretion. J Clin Invest 58:1–6
Korc M, Magun BE (1985) Recycling of epidermal growth factor in a human pancreatic carcinoma cell line. Proc Natl Acad Sci USA 82:6172–6175
Malt RA (1983) Treatment of pancreatic cancer. JAMA 250:1433–1437
Moossa AR, Dawson PJ, Franklin WA, Udekwu AO, Lavella-Jones M (1986) Tumors of the pancreas. In: Moossa AR, Robson MC, Schimpff SC (eds) Comprehensive textbook of oncology. Williams and Wilkins, Baltimore, pp 1105–1132
Paz-Bouza JI, Redding TW, Schally AV (1987) Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinising hormone-releasing hormone. Proc Natl Acad Sci USA 84:1112–1116
Pollard MH, Anderson WAD, Brooks FP, Cohn I Jr, Copeland MM, Connelly RR, Fortner JG, Kissane JM, Lemon HM, Palmer PES, Thomas LB, Webster PD, Carter S (1981) Staging of cancer of pancreas. Cancer of the pancreas task force. Cancer 47:1631
Pousette A, Carlstrom K, Skoldefors H, Wilding N, Theve NO (1982) Purification of partial characterization of 178-estradiol binding macromolecules in the human pancreas. Cancer Res 42:633
Redding TW, Schally AV (1984) Inhibition of growth of pancreatic carcinoma in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 81:248
Schally AV, Redding TW (1987) Somatostatin analogues as adjuncts to agonists of luteiniz-ing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc Natl Acad Sci USA 84:7275–7279
Schally AV, Comaru-Schally AM, Redding TW (1984) Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Ex Biol Med 175:259–281
Setyono-Han B, Henkelman MS, Foekens JA, Klijn JGM (1987) Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47:1566–1570
Skibber JM, Weiss SM, Mohiuddin M, Rosate FE (1985) Impact of radiotherapy on palliative gastroenterostomy in pancreatic cancer. Ann Surg 202:725
Szende B, Srkalovic G, Schally AV, Lapis K, Groot K (1990) Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Cancer 65:2279–2290
Theve NO, Pousette A, Carlström K (1983) Adenocarcinoma of the pancreas — a hormone-sensitive tumor? A preliminary report on novaldex treatment. Clin Oncol 9:193–197
Zalatnai A, Schally AV (1989) Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp6-LH-RH and somatostatin analog RC-160: histological evidence of improvement. Int J Pancreatol 4:149–160
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gonzalez-Barcena, D. (1992). LH-RH Agonists in the Treatment of Pancreatic Cancer. In: Höffken, K. (eds) Peptides in Oncology I. Recent Results in Cancer Research, vol 124. Springer, Milano. https://doi.org/10.1007/978-88-470-2186-0_10
Download citation
DOI: https://doi.org/10.1007/978-88-470-2186-0_10
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2188-4
Online ISBN: 978-88-470-2186-0
eBook Packages: Springer Book Archive